Get the Stockscreener App
0.7614
45.14%
0.2337
Quince Therapeutics Inc stock is traded at $0.7614, with a volume of 704.42M.
It is up +45.14% in the last 24 hours and down -71.53% over the past month.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
See More
Previous Close:
$0.5277
Open:
$0.7151
24h Volume:
704.42M
Relative Volume:
19.85
Market Cap:
$42.61M
Revenue:
-
Net Income/Loss:
$-31.39M
P/E Ratio:
-0.9064
EPS:
-0.84
Net Cash Flow:
$-18.45M
1W Performance:
+382.00%
1M Performance:
-71.53%
6M Performance:
-52.13%
1Y Performance:
-45.29%
1-Day Range:
$0.622
$0.9801
1-Week Range:
$0.1251
$0.9801
52-Week Range:
$0.1251
$4.5499
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
0.7653 | 29.38M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.26 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.90 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.05 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.93 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.01 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics (QNCX) Stock Surges 300% on Strategic Alternative Plans - parameter.io
Quince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors Emerge - Blockonomi
Quince Therapeutics (QNCX) Stock: What’s Behind the 300% Rally? - CoinCentral
Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
Why is Quince Therapeutics stock soaring Tuesday? - MSN
QNCX (Quince Therapeutics) NASDAQ intraday up 182.82% to $0.39: watch strategic-review momentum - Meyka
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why Is Quince Therapeutics Stock Soaring Tuesday? - Benzinga
Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move - TechStock²
Quince Therapeutics Exploring Strategic Alternatives; Stock Soars - Nasdaq
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - PharmiWeb.com
Quince Therapeutics stock soars after engaging LifeSci Capital as advisor By Investing.com - Investing.com Australia
Quince Therapeutics stock soars after engaging LifeSci Capital as advisor - Investing.com
Fed Meeting: What is Quince Therapeutics Incs debt to equity ratio2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
Quince Therapeutics Announces Significant Board of Directors Resignations - The Globe and Mail
Quince stock plunges 95% following failed clinical trial for inherited childhood disease - The Business Journals
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure - Clinical Trials Arena
Why did QNCX stock plummet over 90% today? - MSN
Lucid Cap Mkts Downgrades Quince Therapeutics (NASDAQ:QNCX) to Strong Sell - Defense World
Quince Therapeutics (NASDAQ:QNCX) Cut to Hold at Brookline Capital Management - Defense World
Quince’s eDSP on ice after Neat phase III fails in A-T - BioWorld MedTech
Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground - Citeline News & Insights
This Codere Online Luxembourg Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
QNCX Downgraded to 'Hold' by D. Boral Capital Analyst | QNCX Sto - GuruFocus
Quince Therapeutics (QNCX) Downgraded by Citizens to Market Perf - GuruFocus
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital By Investing.com - Investing.com Nigeria
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital - Investing.com Nigeria
Lucid Capital Markets downgrades Quince Therapeutics stock to Sell after failed trial By Investing.com - Investing.com India
Lucid Capital Markets downgrades Quince Therapeutics stock to Sell after failed trial - Investing.com
Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp - MarketBeat
Quince Therapeutics (QNCX) Downgraded Following Phase 3 Trial Mi - GuruFocus
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics stock rating downgraded by Citizens after Phase 3 trial failure - Investing.com Nigeria
Quince Therapeutics phase 3 trial for rare disease fails to meet endpoints By Investing.com - Investing.com South Africa
Why Did QNCX Stock Plummet Over 90% Today? - Asianet Newsable
Quince Therapeutics Announces Results from Phase 3 NEAT Trial - TradingView
QNCX Stock Plummets 88% After Ceasing eDSP Development - GuruFocus
Quince Therapeutics (QNCX) Shares Drop as Phase 3 Trial Misses K - GuruFocus
Quince Therapeutics phase 3 trial for rare disease fails to meet endpoints - Investing.com Canada
Quince Therapeutics Halts Development of Neurological Drug Candidate; Shares Plunge - marketscreener.com
Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial - TradingView
Quince Therapeutics stock tumbles after failed Phase 3 trial results By Investing.com - Investing.com Nigeria
Quince Therapeutics (QNCX) Faces Setback with Phase 3 Trial Resu - GuruFocus
Quince Therapeutics stock tumbles after failed Phase 3 trial results - Investing.com
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia - Business Wire
Is Quince Therapeutics Inc. stock showing strong momentumFed Meeting & Free Fast Entry Momentum Trade Alerts - mfd.ru
Quince Therapeutics (NASDAQ:QNCX) Given "Buy" Rating at D. Boral Capital - MarketBeat
QNCX: D. Boral Capital Maintains Buy Rating and Price Target | Q - GuruFocus
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
2.39%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):